163 related articles for article (PubMed ID: 38504988)
21. Identification of PANoptosis-Based Prognostic Signature for Predicting Efficacy of Immunotherapy and Chemotherapy in Hepatocellular Carcinoma.
Xiong X; Song Q; Jing M; Yan W
Genet Res (Camb); 2023; 2023():6879022. PubMed ID: 37313428
[TBL] [Abstract][Full Text] [Related]
22. PANoptosis-related genes function as efficient prognostic biomarkers in colon adenocarcinoma.
Liu Y; Wang Y; Feng H; Ma L; Liu Y
Front Endocrinol (Lausanne); 2024; 15():1344058. PubMed ID: 38501104
[TBL] [Abstract][Full Text] [Related]
23. Construction of PANoptosis signature: Novel target discovery for prostate cancer immunotherapy.
Yi X; Li J; Zheng X; Xu H; Liao D; Zhang T; Wei Q; Li H; Peng J; Ai J
Mol Ther Nucleic Acids; 2023 Sep; 33():376-390. PubMed ID: 37547288
[TBL] [Abstract][Full Text] [Related]
24. Systems biology comprehensive analysis on breast cancer for identification of key gene modules and genes associated with TNM-based clinical stages.
Amjad E; Asnaashari S; Sokouti B; Dastmalchi S
Sci Rep; 2020 Jul; 10(1):10816. PubMed ID: 32616754
[TBL] [Abstract][Full Text] [Related]
25. Machine learning and molecular subtype analyses provide insights into PANoptosis-associated genes in rheumatoid arthritis.
Li J; Cui J; Wu L; Liu YB; Wang Q
Arthritis Res Ther; 2023 Dec; 25(1):233. PubMed ID: 38041172
[TBL] [Abstract][Full Text] [Related]
26. A novel hypoxia- and lactate metabolism-related signature to predict prognosis and immunotherapy responses for breast cancer by integrating machine learning and bioinformatic analyses.
Li J; Qiao H; Wu F; Sun S; Feng C; Li C; Yan W; Lv W; Wu H; Liu M; Chen X; Liu X; Wang W; Cai Y; Zhang Y; Zhou Z; Zhang Y; Zhang S
Front Immunol; 2022; 13():998140. PubMed ID: 36275774
[TBL] [Abstract][Full Text] [Related]
27. Integrated machine learning identifies epithelial cell marker genes for improving outcomes and immunotherapy in prostate cancer.
Zhu W; Zeng H; Huang J; Wu J; Wang Y; Wang Z; Wang H; Luo Y; Lai W
J Transl Med; 2023 Nov; 21(1):782. PubMed ID: 37925432
[TBL] [Abstract][Full Text] [Related]
28. PANoptosis-related molecular subtype and prognostic model associated with the immune microenvironment and individualized therapy in pancreatic cancer.
Zhang B; Huang B; Zhang X; Li S; Zhu J; Chen X; Song H; Shang D
Front Oncol; 2023; 13():1217654. PubMed ID: 37519797
[TBL] [Abstract][Full Text] [Related]
29. Construction of a Matrix Cancer-Associated Fibroblast Signature Gene-Based Risk Prognostic Signature for Directing Immunotherapy in Patients with Breast Cancer Using Single-Cell Analysis and Machine Learning.
Huang B; Chen Q; Ye Z; Zeng L; Huang C; Xie Y; Zhang R; Shen H
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685980
[TBL] [Abstract][Full Text] [Related]
30. Integrating single-cell and bulk transcriptomic analyses to develop a cancer-associated fibroblast-derived biomarker for predicting prognosis and therapeutic response in breast cancer.
Li C; Yang L; Zhang Y; Hou Q; Wang S; Lu S; Tao Y; Hu W; Zhao L
Front Immunol; 2023; 14():1307588. PubMed ID: 38235137
[TBL] [Abstract][Full Text] [Related]
31. Current evidence and therapeutic implication of PANoptosis in cancer.
Ocansey DKW; Qian F; Cai P; Ocansey S; Amoah S; Qian Y; Mao F
Theranostics; 2024; 14(2):640-661. PubMed ID: 38169587
[TBL] [Abstract][Full Text] [Related]
32. Construction and validation of a PANoptosis-related lncRNA signature for predicting prognosis and targeted drug response in thyroid cancer.
Li R; Zhao M; Sun M; Miao C; Lu J
PeerJ; 2023; 11():e15884. PubMed ID: 37671354
[TBL] [Abstract][Full Text] [Related]
33. PANoptosis-related molecule CASP2 affects the immune microenvironment and immunotherapy response of hepatocellular carcinoma.
Lou Y; Chen D; Gu Q; Zhu Q; Sun H
Heliyon; 2024 Mar; 10(6):e27302. PubMed ID: 38509889
[TBL] [Abstract][Full Text] [Related]
34. A new 4-gene-based prognostic model accurately predicts breast cancer prognosis and immunotherapy response by integrating WGCNA and bioinformatics analysis.
Chen W; Kang Y; Sheng W; Huang Q; Cheng J; Pei S; Meng Y
Front Immunol; 2024; 15():1331841. PubMed ID: 38370403
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
Williams C; Brunskill S; Altman D; Briggs A; Campbell H; Clarke M; Glanville J; Gray A; Harris A; Johnston K; Lodge M
Health Technol Assess; 2006 Sep; 10(34):iii-iv, ix-xi, 1-204. PubMed ID: 16959170
[TBL] [Abstract][Full Text] [Related]
36. Identification of PANoptosis-relevant subgroups to evaluate the prognosis and immune landscape of patients with liver hepatocellular carcinoma.
Zhang Z; Zhang F; Pang P; Li Y; Chen X; Sun S; Bian Y
Front Cell Dev Biol; 2023; 11():1210456. PubMed ID: 37325556
[TBL] [Abstract][Full Text] [Related]
37. Identification of a PANoptosis-related Gene Signature for Predicting the Prognosis, Tumor Microenvironment and Therapy Response in Breast Cancer.
Yu T; Cheng W; Zhang J; Wang T; Liu Y; Duan Y; Hu A; Feng J; Li M; Li Y; Zhang H; Rong Z; Shang Y; Shakila SS; Ma F; Guo B
J Cancer; 2024; 15(2):428-443. PubMed ID: 38169571
[TBL] [Abstract][Full Text] [Related]
38. Impact of disulfidptosis-associated clusters on breast cancer survival rates and guiding personalized treatment.
Chen X; Hu G; Yu Q
Front Endocrinol (Lausanne); 2023; 14():1256132. PubMed ID: 38116315
[TBL] [Abstract][Full Text] [Related]
39. Identification and validation of Golgi apparatus-related signature for predicting prognosis and immunotherapy response in breast cancer.
Chen X; Tang P; Kong Y; Chen D; Tang K
J Cancer Res Clin Oncol; 2024 Feb; 150(2):61. PubMed ID: 38300336
[TBL] [Abstract][Full Text] [Related]
40. Predicting Prognosis and Immunotherapy Response in Multiple Cancers Based on the Association of PANoptosis-Related Genes with Tumor Heterogeneity.
Wang Y; Zhang B; Zhang Z; Ge J; Xu L; Mao J; Zhou X; Mao L; Xu Q; Sang M
Genes (Basel); 2023 Oct; 14(11):. PubMed ID: 38002938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
